Search

Search Constraints

You searched for: Author/Creator Ottevanger, Petronella

Search Results

1. 2022-RA-1173-ESGO Follow-up in gynecological cancer survivors: an EORTC QLG-GCG survivorship study- trial in progress. (20th October 2022)

2. 2022-RA-598-ESGO Prognostic factors for adverse obstetric outcomes in pregnant cancer patients an update on 2174 cases registered in the INCIP registry. (20th October 2022)

3. Dutch Risk Classification and FIGO 2000 for Gestational Trophoblastic Neoplasia Compared. Issue 9 (1st November 2016)

4. Dutch Risk Classification and FIGO 2000 for Gestational Trophoblastic Neoplasia Compared. Issue 9 (November 2016)

5. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Issue 5 (May 2021)

6. Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer. Issue 7 (15th August 2019)

7. Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer. Issue 7 (September 2019)

8. Pertuzumab Plus Chemotherapy for Platinum-Resistant Ovarian Cancer: Safety Run-in Results of the PENELOPE Trial. Issue 5 (1st June 2016)

9. Pertuzumab Plus Chemotherapy for Platinum-Resistant Ovarian Cancer: Safety Run-in Results of the PENELOPE Trial. Issue 5 (June 2016)

10. Position paper from the Endocrine Task Force of the European Organisation for Research and Treatment of Cancer (EORTC) on the management and shared decision making in patients with low-risk micro papillary thyroid carcinoma. (January 2023)